September 10, 2013 at 14:50 PM EDT
Disappointing Test Results For Neurocrine Biosciences
Neurocrine Biosciences Inc. (Nasdaq: NBIX) reported that its tardive dyskinesia treatment NBI-98854 failed a Phase IIb Kinect study sending the stock price plummeting $4.88 to $11.82.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here